Subject(s)
Clinical Trials as Topic , Coronavirus Infections/prevention & control , Disclosure , Drug Industry , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Public Opinion , Trust , Viral Vaccines , COVID-19 , COVID-19 Vaccines , China , Clinical Trial Protocols as Topic , Clinical Trials as Topic/ethics , Clinical Trials as Topic/standards , Confidentiality/ethics , Confidentiality/legislation & jurisprudence , Coronavirus Infections/epidemiology , Disclosure/ethics , Disclosure/legislation & jurisprudence , Drug Industry/ethics , Drug Industry/legislation & jurisprudence , Drug Industry/standards , Humans , Pneumonia, Viral/epidemiology , Politics , Russia , Safety , United States , Viral Vaccines/adverse effects , Viral Vaccines/pharmacology , Viral Vaccines/standards , Viral Vaccines/therapeutic useSubject(s)
Clinical Trials as Topic , Coronavirus Infections/prevention & control , Drug Approval/legislation & jurisprudence , Drug Industry , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Politics , Research Personnel , Safety , Viral Vaccines/adverse effects , COVID-19 , COVID-19 Vaccines , Clinical Trial Protocols as Topic , Clinical Trials as Topic/ethics , Clinical Trials as Topic/methods , Clinical Trials as Topic/standards , Coronavirus Infections/epidemiology , Disclosure , Drug Industry/ethics , Drug Industry/legislation & jurisprudence , Drug Industry/standards , Humans , Myelitis, Transverse/etiology , Pneumonia, Viral/epidemiology , Public Opinion , Research Personnel/psychology , Sample Size , United Kingdom , United States , United States Food and Drug Administration/legislation & jurisprudence , Viral Vaccines/standardsSubject(s)
Drug Costs/legislation & jurisprudence , Drugs, Generic , Legislation, Drug , Patents as Topic/legislation & jurisprudence , Drug Industry/legislation & jurisprudence , Federal Government , Humans , Prescription Fees/legislation & jurisprudence , United States , United States Food and Drug AdministrationSubject(s)
COVID-19 Vaccines/supply & distribution , COVID-19/prevention & control , Drug Industry/legislation & jurisprudence , Licensure , COVID-19/epidemiology , Drug Approval/legislation & jurisprudence , European Union , Humans , Pandemics/prevention & control , Patents as Topic/legislation & jurisprudence , SARS-CoV-2/immunology , United StatesSubject(s)
2019-nCoV Vaccine mRNA-1273 , Dissent and Disputes , Drug Industry , Inventors/legislation & jurisprudence , National Institutes of Health (U.S.) , Patents as Topic/legislation & jurisprudence , Research Personnel/legislation & jurisprudence , 2019-nCoV Vaccine mRNA-1273/economics , 2019-nCoV Vaccine mRNA-1273/genetics , 2019-nCoV Vaccine mRNA-1273/supply & distribution , Drug Industry/economics , Drug Industry/legislation & jurisprudence , Humans , Inventors/economics , National Institutes of Health (U.S.)/economics , National Institutes of Health (U.S.)/legislation & jurisprudence , Ownership/economics , Ownership/legislation & jurisprudence , Public-Private Sector Partnerships/economics , Public-Private Sector Partnerships/legislation & jurisprudence , Research Personnel/economics , SARS-CoV-2/genetics , United StatesABSTRACT
Proposals to waive intellectual property rights (IPRs) on coronavirus 2019 (COVID-19)-related developments have gained considerable support among politicians, including from US President Biden, academics, nongovernmental organizations (NGOs), the media, and the general public. However, there are surprisingly few reflections about the short- and long-term consequences for medical innovation, particularly the development of new drugs and vaccines. In this feature, I reflect on the consequences for innovative entrepreneurial companies, the incentives to innovate, and consequences for international knowledge flows to low- and middle-income countries. I conclude that waiving IPRs reduces opportunities for entrepreneurial companies to attract sufficient funding for developing medical innovations. Low- and middle-income countries might suffer reduced knowledge inflows in the absence of IPRs that undermine their ability to develop medical innovations.
Subject(s)
Drug Discovery , Drug Industry/trends , Intellectual Property , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , COVID-19 Vaccines/therapeutic use , Developing Countries , Drug Industry/legislation & jurisprudence , Humans , COVID-19 Drug TreatmentSubject(s)
Disruptive Technology/legislation & jurisprudence , Drug Delivery Systems/methods , Drug Development/methods , Drug Industry/legislation & jurisprudence , Biological Products/therapeutic use , Cell- and Tissue-Based Therapy/statistics & numerical data , Contact Lenses , Drug Approval/legislation & jurisprudence , Drugs, Generic , Equipment and Supplies/statistics & numerical data , Genetic Therapy/legislation & jurisprudence , Genetic Therapy/statistics & numerical data , Humans , Japan , United States , United States Food and Drug AdministrationABSTRACT
Compulsory licensing for drug patents is of great significance to ensure the accessibility of drugs. Although the development of China's compulsory licensing system for drug patents has been gradually improved, there are still problems. For example, the scope of the object is not realistic, the setting of the initiating subject is unreasonable, the reasons for issuance are not clear, the duration and scope of the license are not refined, and the provisions on the exploitation fee are missing. Consequently, in order to improve China's compulsory licensing system for drug patents, it is necessary to expand reasonably the scope of the object, remove the restrictions on the initiating subject, adjust the initiating rights of different subjects, determine the duration and scope of the license and the applicability of the hearing on a case-by-case basis, and determine a reasonable exploitation fee by taking into account the national income, patent cost, market share and other factors, in consideration of the flexibly international norms and the actual situation in China.
Subject(s)
Licensure/legislation & jurisprudence , Patents as Topic/legislation & jurisprudence , China , Drug Industry/legislation & jurisprudence , Humans , Legislation, DrugSubject(s)
Drug Approval , Product Surveillance, Postmarketing , Research , Social Control, Formal , United States Food and Drug Administration , Vaccines , Cross-Sectional Studies , Drug Industry/legislation & jurisprudence , Drug Monitoring , Humans , Research/legislation & jurisprudence , United StatesSubject(s)
COVID-19 Vaccines/economics , COVID-19 Vaccines/supply & distribution , COVID-19/prevention & control , Developed Countries/economics , Developing Countries/economics , Drug Industry/economics , Patents as Topic/legislation & jurisprudence , COVID-19/epidemiology , COVID-19/immunology , COVID-19/transmission , Cooperative Behavior , Drug Industry/legislation & jurisprudence , History, 20th Century , Humans , Licensure/legislation & jurisprudence , Pandemics/prevention & control , Pandemics/statistics & numerical data , Penicillins/economics , Penicillins/history , Spike Glycoprotein, Coronavirus/genetics , Spike Glycoprotein, Coronavirus/immunology , United Nations , United States/epidemiology , World Health Organization/organization & administration , World War IIABSTRACT
The urgency and impact of the ongoing COVID-19 pandemic are changing global drug development and regulatory processes. The need for speed to understand the virus and develop new vaccines, medicines, and therapies for patients has provided unprecedented learning opportunities and revealed how the pharmaceutical industry can improve upon traditional processes. To stay competitive while remaining compliant with agency regulations and guidance, companies need to implement new process/tools that allow for more flexible work models, consider expanding the use of decentralized/hybrid trials, and capitalize on the use of real-world evidence (RWE) and cloud-based data systems. In addition, regulatory agencies should retain the agility exhibited during current reviews of potential new therapies, applying this momentum to other areas of unmet medical need. Further, agencies should consider a globally acceptable application platform. This article, by the Pharmaceuticals' Head of Regulatory Affairs at Bayer AG, examines how impacts of the COVID-19 crisis will continue beyond the pandemic period to the benefit of patients, drug developers, regulators, clinicians, and caregivers.
Subject(s)
COVID-19/epidemiology , Drug Development/organization & administration , Drug Industry/legislation & jurisprudence , Teleworking , Drug Development/legislation & jurisprudence , Global Health , Government Agencies , Humans , Pandemics , COVID-19 Drug TreatmentABSTRACT
Shortages of medicines have become a major public health challenge. The aim of this study was to survey national measures to manage and combat these shortages. A questionnaire survey was conducted with public authorities involved in the Pharmaceutical Pricing and Reimbursement Information (PPRI) network. Reponses relating to measures as of March / April 2020 were received from 24 countries (22 European countries, Canada and Israel). In 20 countries, manufacturers are requested to notify - usually on an obligatory basis - upcoming and existing shortages, which are recorded in a register. Further measures include a regular dialogue with relevant stakeholders (18 countries), financial sanctions for manufacturers in cases of non-supply and/or non-compliance with reporting or stocking requirements (15 countries) and simplified regulatory procedures (20 countries). For defined medicines, supply reserves have been established (14 countries), and legal provisions allow the issuing of export bans (10 countries). Some measures have been introduced since the end of 2019 and countries are planning and discussing further action. While governments reacted by taking national measures, the COVID-19 crisis might serve as an opportunity to join forces in cross-country collaboration and develop joint (e.g. European) solutions to address the shortage issue in a sustainable manner. A practical first step could be to work on a harmonisation of the national registers.